NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (en:Method) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (en:Method)
EP (6) EP2277535A3 (en:Method)
JP (4) JP2002539273A (en:Method)
KR (3) KR100798212B1 (en:Method)
CN (3) CN1191852C (en:Method)
AR (3) AR022965A1 (en:Method)
AT (3) ATE459373T1 (en:Method)
AU (3) AU750762B2 (en:Method)
BE (1) BE1025464I2 (en:Method)
BR (4) BR0009163A (en:Method)
CA (3) CA2366314C (en:Method)
CY (3) CY1107561T1 (en:Method)
CZ (3) CZ301445B6 (en:Method)
DE (4) DE122009000054I1 (en:Method)
DK (2) DK1163000T3 (en:Method)
ES (3) ES2339737T3 (en:Method)
FR (1) FR10C0008I2 (en:Method)
HK (3) HK1043730A1 (en:Method)
HU (4) HUP0200664A2 (en:Method)
IL (5) IL145043A0 (en:Method)
LU (1) LU91652I2 (en:Method)
MX (1) MXPA01009452A (en:Method)
MY (2) MY125387A (en:Method)
NL (1) NL300415I1 (en:Method)
NO (4) NO330736B1 (en:Method)
NZ (3) NZ513841A (en:Method)
PL (3) PL204890B1 (en:Method)
PT (2) PT1163000E (en:Method)
SI (2) SI1163000T1 (en:Method)
TR (3) TR200102739T2 (en:Method)
TW (3) TWI286938B (en:Method)
WO (3) WO2000056360A2 (en:Method)

Families Citing this family (289)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
DK0909323T3 (da) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
NZ508927A (en) 1998-05-22 2003-12-19 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
MXPA01009452A (es) * 1999-03-19 2002-08-06 Smithkline Beecham Biolog Vacuna.
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2277896A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
AP1897A (en) * 2001-01-23 2008-10-10 Aventis Pasteur Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
EP2269639B1 (en) 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20050106162A1 (en) 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
EP1506007B1 (en) * 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2775098T3 (es) 2002-10-11 2020-07-23 Glaxosmithkline Biologicals Sa Vacunas de polipĆ©ptidos para protecciĆ³n amplia contra linajes meningocĆ³cicos hipervirulentos
EP1551869A2 (en) * 2002-10-15 2005-07-13 Intercell AG Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
LT2395073T (lt) 2002-11-01 2017-11-10 Glaxosmithkline Biologicals S.A. Džiovinimo būdas
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer Ī²-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposĆ³b wytwarzania wyodrębnionego polisacharydu, sposĆ³b identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5ā€™ cpg nucleic acids and methods of use
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
CN102319427A (zh) * 2003-01-30 2012-01-18 čÆŗ华ē–«č‹—å’ŒčÆŠę–­ęœ‰é™å…¬åø ęŠ—å¤šē§č„‘č†œē‚ŽēƒčŒč”€ęø…ē»„ēš„åÆę³Øå°„ę€§ē–«č‹—
KR20060035581A (ko) 2003-03-07 2006-04-26 ģ™€ģ“ģ–“ģ“° ķ™€ė”©ģŠ¤ ģ½”ķ¬ė ˆģ“ģ…˜ ė³‘ģ›ė‚“ ź°ģ—¼ģ— ėŒ€ķ•œ ė©“ģ—­ķ™”ģ— ģœ ģš©ķ•œė‹¤ė‹¹ė„˜-ģŠ¤ķƒ€ķ•„ė”œģ½”ģ»¤ģŠ¤ ķ‘œė©“ ė¶€ģ°©ģ†Œ ģš“ė°˜ģ²“ ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“
CN101818185B (zh) * 2003-03-13 2016-05-25 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ēŗÆ化ē»†čŒęŗ¶ē»†čƒžē“ ēš„ę–¹ę³•
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
ES2328697T5 (es) 2003-06-02 2017-07-25 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogƩnicas basadas en micropartƭculas que comprenden toxoide adsorbido y un antƭgeno que contiene un polisacƔrido
CN103357002A (zh) * 2003-10-02 2013-10-23 čÆŗ华ē–«č‹—å’ŒčÆŠę–­ęœ‰é™å…¬åø 多ē§č„‘č†œē‚ŽēƒčŒč”€ęø…ē¾¤ēš„ę¶²ä½“ē–«č‹—
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
AU2006208208B2 (en) 2005-01-27 2011-05-19 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
ATE552267T1 (de) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic Immungene von uropathogenen escherichia coli
HUE030881T2 (en) 2005-02-18 2017-06-28 Glaxosmithkline Biologicals Sa Meningitis / sepsis-associated escherichia coli proteins and nucleic acids
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2986862C (en) * 2005-04-08 2022-09-27 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
JP5297800B2 (ja) 2005-06-27 2013-09-25 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©
BRPI0615420A2 (pt) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic vacinaĆ§Ć£o mĆŗltipla que inclui meningococo do sorogrupo c
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101441368B1 (ko) 2005-12-22 2014-09-24 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜ ģ»Øģ„¬ź²Œģ“ķŠø ė°±ģ‹ 
CA2636566C (en) * 2006-01-17 2018-03-13 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
EP1993604B1 (en) * 2006-03-17 2015-12-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ATE554788T1 (de) 2006-03-22 2012-05-15 Novartis Ag Schemata zur immunisierung mit meningokokken- konjugaten
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US20100021503A1 (en) * 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
JO3420B1 (ar) * 2006-03-30 2019-10-20 Brigham & Womens Hospital Inc ŲŖŲ±ŁƒŁŠŲØŲ© ŲµŁŠŲÆŁ„Ų§Ł†ŁŠŲ© ŁˆŁ„Ł‚Ų§Ų­ Ł„Ł„ŁˆŁ‚Ų§ŁŠŲ© Ł…Ł† Ų§ŲµŲ§ŲØŲ§ŲŖ Ų§Ł„Ł…ŁƒŁˆŲ±Ų© Ų§Ł„Ų¹Ł‚ŲÆŁŠŲ©
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhƦsiner
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
JP2010500399A (ja) 2006-08-16 2010-01-07 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ å°æč·Æē—…åŽŸę€§å¤§č…ø菌ē”±ę„ć®å…ē–«åŽŸ
PT2074221E (pt) * 2006-10-10 2010-09-06 Wyeth Llc MĆ©todos melhorados para a separaĆ§Ć£o de polissacĆ”ridos tipo 3 de streptococcus pneumoniae
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2167120A2 (en) * 2007-06-26 2010-03-31 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BRPI0816689B1 (pt) 2007-09-12 2021-08-24 Novartis Ag ComposiĆ§Ć£o de vacina, kit e mĆ©todo para a confecĆ§Ć£o de uma composiĆ§Ć£o de vacina para a prevenĆ§Ć£o ou tratamento de infecĆ§Ć£o por streptococcus pyogenes
JP5701058B2 (ja) 2007-10-19 2015-04-15 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ é«„č†œē‚ŽčŒćƒÆć‚Æćƒćƒ³å‡¦ę–¹ē‰©
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducciĆ³n de respuestas inmunes
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
BRPI0821240B8 (pt) 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
US8226959B2 (en) * 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
EP2245048B1 (en) 2008-02-21 2014-12-31 Novartis AG Meningococcal fhbp polypeptides
EP2631245A1 (en) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
EP3312158A1 (en) 2008-07-21 2018-04-25 The Brigham and Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
EP2349520B1 (en) 2008-10-27 2016-05-25 GlaxoSmithKline Biologicals SA Purification method for carbohydrate from group a streptococcus
KR101634058B1 (ko) 2008-12-09 2016-06-27 ķ™”ģ“ģž ė°±ģ‹ ģŠ¤ ģ—˜ģ—˜ģ”Ø ļ¼©ļ½‡ļ¼„ ļ¼£ļ¼Øļ¼“ ķŽ©ķ‹°ė“œ ė°±ģ‹ 
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
NZ593674A (en) 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
CA2749367A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinaƧƵes de proteĆ­na de ligaĆ§Ć£o de fator h meningocĆ³cico e conjugados de sacarĆ­deos pneumocĆ³cicos
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
JP5395264B2 (ja) 2009-06-22 2014-01-22 ćƒÆć‚¤ć‚¹ćƒ»ć‚Ø惫ć‚Øćƒ«ć‚·ćƒ¼ é»„č‰²ćƒ–ćƒ‰ć‚¦ēƒčŒļ¼ˆļ½“ļ½”ļ½ļ½ļ½ˆļ½™ļ½Œļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½•ļ½’ļ½…ļ½•ļ½“ļ¼‰ęŠ—åŽŸć®å…ē–«åŽŸę€§ēµ„ęˆē‰©
NZ597191A (en) 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
CN102596236B (zh) 2009-07-30 2015-06-24 č¾‰ē‘žē–«č‹—ęœ‰é™č“£ä»»å…¬åø ęŠ—åŽŸę€§Tauč‚½åŠå…¶ē”Ø途
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
MX2012002639A (es) * 2009-09-03 2012-03-14 Pfizer Vaccines Llc Vacuna de pcsk9.
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
JP5960055B2 (ja) 2009-10-27 2016-08-02 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ę”¹å¤‰é«„č†œē‚ŽčŒļ½†ļ¼Øļ¼¢ļ¼°ćƒćƒŖ惚惗惁惉
LT2493498T (lt) 2009-10-30 2017-05-25 Glaxosmithkline Biologicals Sa Staphylococcus aureus 5 tipo ir 8 tipo kapsulinių sacharidų gryninimas
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
SG10201506162RA (en) 2009-12-17 2015-09-29 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
RU2581020C2 (ru) 2009-12-22 2016-04-10 Š”ŠµŠ»Š»Š“ŠµŠŗс Š¢ŠµŃ€Š°ŠæьютŠøŠŗс, Š˜Š½Šŗ. ŠšŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø Š²Š°ŠŗцŠøŠ½
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
AU2011238670B2 (en) 2010-03-30 2015-04-23 Children's Hospital & Research Center Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US20110251156A1 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
WO2011146910A1 (en) * 2010-05-20 2011-11-24 Round June L Antigen specific tregs and related compositions, methods and systems
SI2575870T1 (sl) * 2010-06-04 2017-01-31 Wyeth Llc Formulacije cepiva
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinaciĆ³n con menores dosis de antĆ­geno y/o adyuvante
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2688590B1 (en) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
WO2012154072A1 (ru) 2011-05-06 2012-11-15 Aparin Petr Gennadievich Š­ŠŗŠ·Š¾ŠæŠ¾Š»ŠøсŠ°Ń…Š°Ń€ŠøŠ“ Š±Š°ŠŗтŠµŃ€ŠøŠø shigella sonnei, сŠæŠ¾ŃŠ¾Š± ŠµŠ³Š¾ ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя Šø Š²ŠŗŠ»ŃŽŃ‡Š°ŃŽŃ‰ŠøŠµ ŠµŠ³Š¾ Š²Š°ŠŗцŠøŠ½Š° Šø фŠ°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠµŃŠŗŠ°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøя
CN107837394A (zh) 2011-06-24 2018-03-27 埃ēš®ę‰˜å‰å°¼č„æę–Æęœ‰é™å…¬åø 作äøŗęŠ—åŽŸē‰¹å¼‚ę€§å…ē–«č°ƒčŠ‚剂ēš„åŒ…å«é€‰ę‹©ēš„č½½ä½“ć€ē»“ē”Ÿē“ ć€å•å®å’Œē±»é»„é…®ēš„ē»„合ēš„čÆē‰©ē»„合ē‰©
JP6088507B2 (ja) 2011-07-08 2017-03-01 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ćƒćƒ­ć‚·ćƒ³ćƒ©ć‚¤ć‚²ćƒ¼ć‚·ćƒ§ćƒ³ć®ę–¹ę³•
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CN103917245B (zh) 2011-09-14 2017-06-06 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽåˆ¶å¤‡ē³–ā€‘蛋ē™½č“Øē³–ē¼€åˆē‰©ēš„ę–¹ę³•
WO2013043518A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
CN103974718A (zh) 2011-12-08 2014-08-06 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø åŸŗäŗŽč‰°éš¾ę¢­čŒęƒē“ ēš„ē–«č‹—
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
AU2013224026A1 (en) 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
JP2015510872A (ja) 2012-03-07 2015-04-13 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼³ļ½”ļ½’ļ½…ļ½ļ½”ļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½Žļ½…ļ½•ļ½ļ½ļ½Žļ½‰ļ½ļ½…ęŠ—åŽŸć®å¢—å¼·ć•ć‚ŒćŸč£½å‰¤
CN104159603A (zh) 2012-03-08 2014-11-19 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø åø¦ęœ‰tlr4ęæ€åŠØ剂ēš„č”åˆē–«č‹—
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
AU2013254751B2 (en) 2012-04-26 2017-12-14 Glaxosmithkline Biologicals S.A. Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
CA2874210A1 (en) 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
KR102057217B1 (ko) 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
BR112015004515A2 (pt) 2012-10-03 2018-05-22 Novartis Ag composiĆ§Ć£o imunogĆŖnica
CA2886938A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
CA2888321A1 (en) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa AdministraciĆ³n intradĆ©rmica de composiciones inmunolĆ³gicas que comprenden agonistas del receptor de tipo Toll
CA2911826C (en) 2013-05-10 2022-08-23 California Institute Of Technology Probiotic prevention and treatment of colon cancer
CA2909586C (en) 2013-05-15 2021-08-31 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN105934251A (zh) * 2014-01-21 2016-09-07 č¾‰ē‘žå¤§čÆ厂 č‚ŗē‚Žé“¾ēƒčŒčšč†œå¤šē³–及其ē¼€åˆē‰©
PE20161095A1 (es) 2014-01-21 2016-10-26 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
CR20170020A (es) 2014-07-23 2017-08-10 ChildrenĀ“S Hospital & Res Center At Oakland Variantes de proteĆ­nas de uniĆ³n al factor h y mĆ©todos de uso de estas
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
EP3244917B1 (en) 2015-01-15 2023-04-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
KR102800419B1 (ko) 2015-07-21 2025-04-25 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ ‘ķ•©ėœ ģŗ”ģŠķ˜• ģ‚¬ģ¹“ė¼ģ“ė“œ ķ•­ģ›ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼, ź·øė„¼ ķ¬ķ•Øķ•˜ėŠ” ķ‚¤ķŠø ė° ź·øģ˜ ģš©ė„
JP7223989B2 (ja) 2015-08-25 2023-02-17 ć‚¢ć‚°ćƒ©ćƒÆ惫ļ¼Œćƒćƒ“ć‚æ 免ē–«čŖæēƀēµ„ęˆē‰©ćŠć‚ˆć³ćć®ä½æē”Øę–¹ę³•
CA3000313A1 (en) 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
RU2021109510A (ru) 2015-12-04 2021-04-16 Š”Š°Š½Š°-Š¤Š°Ń€Š±ŠµŃ€ ŠšŃŠ½ŃŠµŃ€ Š˜Š½ŃŃ‚Šøтьют, Š˜Š½Šŗ. Š’Š°ŠŗцŠøŠ½Š°Ń†Šøя с ŠøсŠæŠ¾Š»ŃŒŠ·Š¾Š²Š°Š½ŠøŠµŠ¼ Š°Š»ŃŒŃ„Š° 3 Š“Š¾Š¼ŠµŠ½Š° mica/b Š“Š»Ń Š»ŠµŃ‡ŠµŠ½Šøя рŠ°ŠŗŠ°
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
WO2017125844A1 (en) 2016-01-19 2017-07-27 Pfizer Inc. Cancer vaccines
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
EP3474890A1 (en) * 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Fƶrderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
CN109862908B (zh) 2016-08-05 2023-05-02 圣čÆŗč²Ā·åø•ę–Æ图尔公åø 多价č‚ŗē‚ŽēƒčŒå¤šē³–-蛋ē™½č“Øē¼€åˆē‰©ē»„合ē‰©
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
CN117801069A (zh) 2016-10-07 2024-04-02 ꁩē‰¹ē½—姆公åø ē”ØäŗŽē™Œē—‡ē–—ę³•ēš„免ē–«åŽŸę€§åŒ–合ē‰©
CN117801066A (zh) 2016-10-07 2024-04-02 ꁩē‰¹ē½—姆公åø ē”ØäŗŽē™Œē—‡ē–—ę³•ēš„免ē–«åŽŸę€§åŒ–合ē‰©
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
DK3570879T3 (da) 2017-01-20 2022-04-11 Pfizer Immunogene sammensƦtninger til anvendelse i pneumokokvacciner
JP7010961B2 (ja) 2017-01-31 2022-02-10 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ é«„č†œē‚ŽčŒēµ„ęˆē‰©ćŠć‚ˆć³ćć®ę–¹ę³•
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110520154B (zh) * 2017-03-15 2023-08-04 ę Ŗ式会ē¤¾Lg化学 多价č‚ŗē‚Žé“¾ēƒčŒē–«č‹—ē»„合ē‰©
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
KR102634811B1 (ko) 2017-06-10 2024-02-06 ģøė²¤ķŠøķ”„ė¼ģ“ģ¦ˆ ģøķ¬. ė©“ģ—­ģ›ģ„±ź³¼ ķ•­ģ›ķ•­ģ²“ ź²°ķ•©ģ„±ģ“ ź°œģ„ ėœ 2ź°€ ė˜ėŠ” ė‹¤ź°€ ģ ‘ķ•©ģ²“ ė‹¤ė‹¹ė„˜ė„¼ ź°€ģ§„ ė‹¤ź°€ ģ ‘ķ•©ģ²“ ė°±ģ‹ 
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
MX2020001820A (es) 2017-08-14 2020-03-20 Glaxosmithkline Biologicals Sa Metodos para reforzar las respuestas inmunitarias.
EP3691677A4 (en) 2017-10-04 2021-07-07 Pogona, Llc COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
AU2018400751B2 (en) 2017-12-06 2022-07-21 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR102812816B1 (ko) 2018-02-05 2025-05-27 ģ‚¬ė…øķ”¼ ķŒŒģŠ¤ķ‡“ė„“ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‹¤ź°€ ķė “źµ¬ź· ģ„± ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
EP3749357A4 (en) 2018-02-05 2022-04-20 Sanofi Pasteur, Inc. POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
MX2020010701A (es) 2018-04-11 2021-01-20 Enterome S A PĆ©ptidos antigĆ©nicos para la prevenciĆ³n y el tratamiento del cĆ”ncer.
KR20190121713A (ko) 2018-04-18 2019-10-28 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤(ģ£¼) ģŠ¤ķŠøė ™ķ† ģ½”ģ»¤ģŠ¤ ė‰“ėŖØė‹ˆģ•  ķ˜‘ė§‰ ė‹¤ė‹¹ė„˜ ė° ź·øģ˜ ė©“ģ—­ģ›ģ„± ģ ‘ķ•©ģ²“
EP3824019A1 (en) 2018-07-19 2021-05-26 GlaxoSmithKline Biologicals SA Processes for preparing dried polysaccharides
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7551618B2 (ja) 2018-12-12 2024-09-17 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ļ¼Æļ¼ēµåˆåž‹ć‚°ćƒŖć‚³ć‚·ćƒ«åŒ–ć®ćŸć‚ć®äæ®é£¾ć‚­ćƒ£ćƒŖć‚¢ć‚æćƒ³ćƒ‘ć‚Æč³Ŗ
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CN119971019A (zh) 2018-12-19 2025-05-13 é»˜ę²™äøœęœ‰é™č“£ä»»å…¬åø 包含č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-蛋ē™½ē¼€åˆē‰©ēš„ē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
CA3126492A1 (en) 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020212461A1 (en) 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
CA3139257A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
EP4010014A1 (en) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN114245746A (zh) 2019-08-05 2022-03-25 č‘›å…°ē“ å²å…‹ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽåˆ¶å¤‡åŒ…å«č›‹ē™½då¤šč‚½ēš„ē»„合ē‰©ēš„ę–¹ę³•
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
JP2021087420A (ja) 2019-11-01 2021-06-10 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ļ¼„ļ½“ļ½ƒļ½ˆļ½…ļ½’ļ½‰ļ½ƒļ½ˆļ½‰ļ½ ļ½ƒļ½ļ½Œļ½‰ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ę–¹ę³•
HUE065075T2 (hu) 2019-11-15 2024-04-28 Enterome S A AntigƩn peptidek B-sejtes malignitƔs megelƵzƩsƩre Ʃs kezelƩsƩre
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20220409539A1 (en) * 2019-12-30 2022-12-29 Fraunhofer Usa Inc. Particles for multi-dose delivery
EP4107192A1 (en) 2020-02-21 2022-12-28 Pfizer Inc. Purification of saccharides
KR20220143910A (ko) 2020-02-23 2022-10-25 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ—ģŠ¤ģ¼€ė¦¬ķ‚¤ģ•„ ģ½œė¼ģ“ ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ė°©ė²•
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
JP7630603B2 (ja) 2020-08-10 2025-02-17 ć‚¤ćƒ³ćƒ™ćƒ³ćƒˆćƒ—ćƒ©ć‚¤ć‚ŗćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ å‡ŗē¾č”€ęø…åž‹ļ¼’ļ¼”ļ½†ć‚’å«ć‚€å¤šä¾”č‚ŗē‚ŽēƒčŒč¤‡åˆē³–č³ŖćƒÆć‚Æćƒćƒ³
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
IL302413A (en) 2020-11-04 2023-06-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
EP4294432A1 (en) 2021-02-19 2023-12-27 Sanofi Pasteur, Inc. Meningococcal b recombinant vaccine
JP2024510717A (ja) 2021-02-22 2024-03-11 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©ć€ä½æē”ØåŠć³ę–¹ę³•
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
EP4346892A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN118434441A (zh) 2021-11-18 2024-08-02 马ē‰¹é‡Œē“¦å…‹ę–Æ公åø 免ē–«åŽŸę€§čžåˆč›‹ē™½ē»„合ē‰©å’Œå…¶ä½æē”Øę–¹ę³•
JP2025508749A (ja) 2022-01-13 2025-04-10 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć•ć›ćŸčŽ¢č†œē³–ęŠ—åŽŸć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ä½æē”Ø
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
AU2023246941A1 (en) 2022-03-31 2024-10-24 Enterome S.A. Antigenic peptides for prevention and treatment of cancer.
IL316477A (en) 2022-05-11 2024-12-01 Pfizer Process for producing vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (en) 2022-11-22 2025-10-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2023403045A1 (en) 2022-12-01 2025-06-12 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
CN120404993B (zh) * 2025-07-03 2025-10-03 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0449856B1 (en) * 1988-12-16 2001-09-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
SG90042A1 (en) 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
DE69331437T2 (de) * 1992-09-16 2002-09-05 The University Of Tennessee Research Corp., Knoxville Antigene des hybriden m-proteins und trƤger fĆ¼r gruppe a streptokokkenimpfstoff
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
EP1300156A3 (en) 1993-05-18 2003-05-07 The Ohio State University Research Foundation Otitis media vaccine
ES2210262T3 (es) 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation OligonucleĆ³tidos inmunmoduladores.
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
KR19990007858A (ko) * 1995-04-17 1999-01-25 ģ”“ ė”ėø”ģœ .ė”œģš° ė°•ķ…Œė¦¬ģ•„ģ˜ ė¦¬ķ¬ķ”„ė”œķ…Œģøģœ¼ė”œ ķ“ė¦¬ģ‚¬ģ¹“ė¼ģ“ė“œģ— ėŒ€ķ•œ ė©“ģ—­ė°˜ģ‘ģ˜ ģœ ė„ė° ź°•ķ™”
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
KR19990022742A (ko) 1995-06-07 1999-03-25 ģƒ¤ė„“ė ˆ ģ•„. ķ…Œģ‹œģ—ė„“ ģŠ¤ķŠøė ™ķ† ģ½”ģ»¤ģŠ¤ ģ† ģœ ėž˜ģ˜ hsp70 ź³„ģ—“ģ˜ ģ‡¼ķ¬ ė‹Øė°±ģ§ˆ
HUP9802199A3 (en) 1995-06-07 1999-07-28 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
ATE323721T1 (de) 1996-05-01 2006-05-15 Univ Rockefeller Cholin-bindendes protein, welches als gegen pneumokokken gerichtetes vakzin verwendet wird
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
NZ501911A (en) 1997-06-03 2001-12-21 Connaught Lab Lactoferrin receptor genes (Lbp1, Lbp2 and/or ORF3) of Moraxella to be used in diagnosis or treatment of Moraxella related diseases such conjunctivitis, sinusitis or urogenital infections
HUP0002475A3 (en) 1997-07-21 2002-01-28 Baxter Healthcare S A Wallisel Modified immunogenic pneumolysin compositions as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
DE69942176D1 (de) 1998-04-07 2010-05-06 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC Ī²-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
EP2050464B1 (en) * 1998-12-21 2019-08-07 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
MXPA01009452A (es) * 1999-03-19 2002-08-06 Smithkline Beecham Biolog Vacuna.
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
PL355178A1 (en) 2004-04-05
MXPA01009452A (es) 2002-08-06
TR200102739T2 (tr) 2001-12-21
TR200102735T2 (tr) 2002-04-22
IL145044A (en) 2007-03-08
HK1043728A1 (en) 2002-09-27
JP5551579B2 (ja) 2014-07-16
AU3430700A (en) 2000-10-09
PL204890B1 (pl) 2010-02-26
FR10C0008I1 (fr) 2010-03-26
NO20014325D0 (no) 2001-09-05
AR022964A1 (es) 2002-09-04
NZ513841A (en) 2001-09-28
HUP0200373A2 (en) 2002-06-29
IL145043A (en) 2007-06-17
HUP0200367A2 (en) 2002-05-29
HUP0200664A2 (en) 2002-06-29
HK1043731A1 (en) 2002-09-27
US20060002961A1 (en) 2006-01-05
US20030147922A1 (en) 2003-08-07
CN1191852C (zh) 2005-03-09
KR100642044B1 (ko) 2006-11-10
PL355180A1 (en) 2004-04-05
IL145043A0 (en) 2002-06-30
CN1351503A (zh) 2002-05-29
DE60038166T2 (de) 2009-03-12
KR20020000549A (ko) 2002-01-05
PL355264A1 (en) 2004-04-05
BRPI0009163B1 (pt) 2019-04-09
HU229968B1 (hu) 2015-03-30
HK1043730A1 (zh) 2002-09-27
ATE459373T1 (de) 2010-03-15
AU750788B2 (en) 2002-07-25
EP1776962A1 (en) 2007-04-25
JP2002540074A (ja) 2002-11-26
JP4846906B2 (ja) 2011-12-28
EP1162999B1 (en) 2006-11-29
NO2011014I1 (no) 2011-09-19
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
BR0009154A (pt) 2001-12-26
EP2277535A3 (en) 2011-03-09
NO2011014I2 (no) 2011-08-30
CY1107561T1 (el) 2013-03-13
WO2000056359A3 (en) 2001-02-01
NZ513842A (en) 2004-05-28
DK1163000T3 (da) 2008-04-28
CA2365296A1 (en) 2000-09-28
DE60038166D1 (de) 2008-04-10
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
EP1163000A2 (en) 2001-12-19
NO20014322D0 (no) 2001-09-05
EP1880735A2 (en) 2008-01-23
US9168313B2 (en) 2015-10-27
HUS1500040I1 (hu) 2018-05-28
TWI286938B (en) 2007-09-21
IL145044A0 (en) 2002-06-30
CZ301445B6 (cs) 2010-03-03
ES2300255T3 (es) 2008-06-16
DE60043930D1 (de) 2010-04-15
CN1192798C (zh) 2005-03-16
HK1043728B (en) 2007-06-22
ATE346608T1 (de) 2006-12-15
JP2011057713A (ja) 2011-03-24
US20100119544A1 (en) 2010-05-13
BR0009166A (pt) 2001-12-26
CY2009014I1 (el) 2010-07-28
TWI281403B (en) 2007-05-21
CA2366314C (en) 2012-01-10
SI1162999T1 (sl) 2007-04-30
KR100798212B1 (ko) 2008-01-24
LU91652I9 (en:Method) 2019-01-03
NO20014323D0 (no) 2001-09-05
BE1025464I2 (en:Method) 2019-03-06
NL300415I1 (nl) 2009-12-01
US20110217329A1 (en) 2011-09-08
EP1163000B1 (en) 2008-02-27
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
DE60032120D1 (de) 2007-01-11
JP2002539273A (ja) 2002-11-19
NO20014322L (no) 2001-11-14
EP1162998A2 (en) 2001-12-19
MY125202A (en) 2006-07-31
PL203917B1 (pl) 2009-11-30
AU750913B2 (en) 2002-08-01
CZ20013379A3 (cs) 2002-03-13
CY1107390T1 (el) 2010-07-28
EP2277535A2 (en) 2011-01-26
HU228499B1 (en) 2013-03-28
US20060093626A1 (en) 2006-05-04
WO2000056360A2 (en) 2000-09-28
NO330532B1 (no) 2011-05-09
NO20014325L (no) 2001-11-14
CZ20013378A3 (cs) 2002-03-13
JP2002540075A (ja) 2002-11-26
EP1880735A3 (en) 2008-03-12
WO2000056360A3 (en) 2001-01-25
TWI235064B (en) 2005-07-01
CN1351501A (zh) 2002-05-29
WO2000056359A2 (en) 2000-09-28
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
ES2339737T3 (es) 2010-05-25
BRPI0009163B8 (pt) 2021-05-25
US8926985B2 (en) 2015-01-06
AU750762B2 (en) 2002-07-25
AR022965A1 (es) 2002-09-04
AU3813600A (en) 2000-10-09
CZ303653B6 (cs) 2013-01-30
HK1043731B (en) 2009-01-23
BR0009163A (pt) 2001-12-26
PT1162999E (pt) 2007-02-28
MY125387A (en) 2006-07-31
WO2000056358A2 (en) 2000-09-28
AR022963A1 (es) 2002-09-04
CY2009014I2 (el) 2010-07-28
NZ513840A (en) 2004-02-27
KR20020001785A (ko) 2002-01-09
ATE387214T1 (de) 2008-03-15
DE60032120T2 (de) 2007-09-20
DK1162999T3 (da) 2007-03-26
LU91652I2 (fr) 2010-10-13
CA2366314A1 (en) 2000-09-28
IL145045A0 (en) 2002-06-30
EP1162999A2 (en) 2001-12-19
AU3291900A (en) 2000-10-09
KR20020000785A (ko) 2002-01-05
DE122009000054I1 (de) 2009-12-31
SI1163000T1 (sl) 2008-06-30
EP1162998B1 (en) 2010-03-03
WO2000056358A3 (en) 2001-01-04
US20050031646A1 (en) 2005-02-10
TR200102736T2 (tr) 2002-04-22
FR10C0008I2 (fr) 2012-10-26
CN1391481A (zh) 2003-01-15
NO330736B1 (no) 2011-06-27

Similar Documents

Publication Publication Date Title
BE2018C020I2 (en:Method)
BE2015C057I2 (en:Method)
BE2016C007I2 (en:Method)
BE2015C018I2 (en:Method)
BE2014C017I2 (en:Method)
BE2013C051I2 (en:Method)
BE2013C020I2 (en:Method)
BE2013C015I2 (en:Method)
BE2013C001I2 (en:Method)
BE2012C036I2 (en:Method)
NL300415I2 (en:Method)
BE2008C046I2 (en:Method)
BE2010C011I2 (en:Method)
JP2002514480A5 (en:Method)
BRPI0017527B8 (en:Method)
IN2001KO01233A (en:Method)
JP2002521141A5 (en:Method)
BE2008C047I2 (en:Method)
BE2011C004I2 (en:Method)
BRPI0001672A2 (en:Method)
JP2002521591A5 (en:Method)
JP2002517184A5 (en:Method)
JP2002519925A5 (en:Method)
JP2002513244A5 (en:Method)
JP2002506962A5 (en:Method)